Is Eli Lilly's Dominance in Weight Loss Facing Challenges?

Eli Lilly’s Dominance in the Weight Loss Drug Market

In the last two years, Eli Lilly (NYSE: LLY) has emerged as the frontrunner in the weight management pharmaceutical sector. This success is largely attributed to tirzepatide, marketed as Zepbound for obesity and Mounjaro for diabetes, which became the world’s top-selling medication in 2025.

While Zepbound is poised to benefit from the rapidly expanding demand for weight loss treatments for the foreseeable future, several competitors are eager to challenge Eli Lilly’s position. Over the past quarter, multiple companies have reported encouraging phase 2 and phase 3 clinical trial outcomes for drugs that could potentially rival Zepbound. Does this mean Eli Lilly’s primary growth engine is at risk?

Key Challengers in the Weight Loss Drug Arena

Numerous pharmaceutical and biotechnology firms are seeking a foothold in this lucrative market, but only a select few seem poised to truly compete with Eli Lilly. Let’s highlight three notable contenders:

• Regeneron has teamed up with a Chinese pharmaceutical partner to develop olatorepatide, a GLP-1-based therapy. Regeneron holds commercialization rights outside China. In a recent phase 3 trial conducted in China, patients using olatorepatide achieved an average weight reduction of up to 19% over 48 weeks.
• Roche announced promising phase 2 results for its drug candidate CT-388 earlier this year. Like Zepbound and olatorepatide, CT-388 is a dual GLP-1/GIP agonist. The study showed a placebo-adjusted weight loss of 22.5% after 48 weeks.
• Novo Nordisk, a leading Danish pharmaceutical company, is collaborating with a Chinese firm to develop UBT251, a triple agonist targeting GLP-1, GIP, and glucagon. In a recent phase 2 Chinese study, UBT251 achieved an average weight loss of 19.7% within just 24 weeks.

It’s worth noting that olatorepatide’s efficacy is similar to Zepbound’s, which demonstrated a 20.2% weight loss in a 72-week phase 3 trial. Both drugs act as dual GLP-1/GIP agonists, mimicking two gut hormones to potentially enhance effectiveness.

Can Eli Lilly Maintain Its Leadership?

Despite these promising developments, none of these rival drugs are expected to reach the U.S. market in the near future. Roche and Novo Nordisk still need to complete phase 3 trials, and Regeneron’s successful study was conducted in China, which may not be sufficient for U.S. regulatory approval. It will likely be several years before any of these candidates can directly compete with Zepbound in the U.S.

Novo Nordisk’s CagriSema is anticipated to be the next major entrant, but it is unlikely to pose a significant threat to Eli Lilly, as studies have shown Zepbound outperforms CagriSema. Additionally, Eli Lilly is advancing its own pipeline, including orforglipron, an oral GLP-1 therapy expected to launch soon. This drug could capture a leading share of the oral weight loss market due to its strong phase 3 results and lack of dietary restrictions.

Another promising candidate from Eli Lilly is retatrutide, a triple agonist that recently demonstrated an impressive 28.7% average weight loss in clinical trials.

Although competition in the weight loss sector is intensifying, Eli Lilly is well-positioned to benefit the most. Over the next five years, the company is expected to continue delivering robust financial performance. In 2025, Eli Lilly’s revenue soared by 45% year-over-year to $65.2 billion, and earnings per share nearly doubled to almost $23.

Beyond its core focus, Eli Lilly maintains a diversified portfolio and is investing heavily in technology, particularly artificial intelligence, to accelerate drug discovery. These initiatives could yield significant rewards in the future. Given its continued dominance and strategic strengths, Eli Lilly remains an attractive investment opportunity.

Is Now the Time to Invest in Eli Lilly?

Before making an investment decision regarding Eli Lilly, consider this:

The Motley Fool Stock Advisor team has recently identified what they believe are the 10 best stocks to buy right now—and Eli Lilly is not among them. The selected stocks have the potential to deliver substantial returns in the coming years.

For example, if you had invested $1,000 in Netflix when it was recommended on December 17, 2004, your investment would now be worth $508,607. Similarly, a $1,000 investment in Nvidia on April 15, 2005, would have grown to $1,122,746.

Currently, Stock Advisor boasts an average return of 933%, far outpacing the S&P 500’s 188%. Don’t miss the latest top 10 picks, available through Stock Advisor, and join a community of individual investors.

*Stock Advisor returns as of March 13, 2026.

Is Eli Lilly's Weight Loss Empire in Trouble? was originally published by The Motley Fool.